Mavenir in Collaboration with Intel Delivers Optimised Performance and Power Efficiency for 4G and 5G Open vRAN Solution
24.2.2024 14:37:00 EET | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces availability of its cutting-edge Open vRAN solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost – delivering a cloud-native, high-performance and energy-efficient solution for latency-sensitive and compute-intensive mobile network applications. The move to Intel’s recent processors for vRAN marks the latest solution optimisation for Mavenir, which has driven Open RAN momentum through three generations of Intel Xeon Scalable processors.
Mavenir's Open vRAN solution, powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost, offers an exceptional suite of performance, functionality, and integrated artificial intelligence (AI) and machine learning (ML) application for the next generation 4G and 5G networks. Mavenir has built a close and long-standing technology collaboration with Intel, and the adoption of Intel’s processors enables the development of more efficient and cost-effective RANs. These optimisations are being achieved through the availability of more processing power with higher capacity, resulting in reduction of number of cores or servers needed per cell site.
Mavenir's Open vRAN solution comprises the virtualised distributed Unit (vDU) and the centralised unit (vCU), supporting all mobile network generations (2G, 4G, 5G) and providing a complete baseband unit (BBU) functionality. The solution is cloud-native and easily deployable on Intel architecture-based private, hybrid, or public clouds. The Mavenir vDU incorporates Intel’s FlexRAN reference software, which utilises modular, virtualised control functions across well-defined interfaces that allow flexible and programmable control of the layer 1 wireless infrastructure.
The fully integrated vRAN acceleration feature of 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost eliminates the need for an external acceleration card and delivers up to 2x capacity increase with an additional 20% power savings1 versus the previous generation processor for applications like massive MIMO (mMIMO). This fully integrated solution allows Mobile Network Operators (MNOs) to deploy cloud-native, energy-efficient and AI-driven RAN solutions at a significantly lower cost.
Mavenir's pioneering Open vRAN solution has driven significant industry progress for Open RAN technology, and made Open RAN a mainstream consideration for all operators expanding their 4G and 5G networks, whether building new networks from scratch or upgrading existing ones. The combination sets the stage for more significant advances in next-generation O-RANs including dramatic energy savings, RAN slice assurance, AI/ML-powered SLAs, expanded RAN capacity, and optimised functionality splits.
BG Kumar, President, Access Networks, Platforms and Digital Enablement for Mavenir commented: “Mavenir values our ongoing collaboration with Intel, which is leading the industry in driving forward high-performance and sustainable Open vRAN solutions for 4G and 5G networks. Mavenir’s integrated solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost optimises the Open vRAN solution offerings even further– giving CSPs worldwide the ability to deploy cloud-native, energy-efficient, and cost-effective AI/ML powered RAN infrastructure built on world-class technology.”
Cristina Rodriguez, Vice President and General Manager, Wireless Access Networking Division at Intel said: “Operators’ journey to design and deploy new networks drives a key set of technology needs and challenges to be addressed. Mavenir’s solution leverages the best features of Intel’s 4th Gen Intel Xeon platform to provide operators a flexible solution with advanced functionalities to meet the diverse needs of both greenfield and brownfield operators.”
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realise the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
____________________________
1 For workloads and configurations visit www.Intel.com/PerformanceIndex. Results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223458554/en/
Contact information
Mavenir PR Contact:
Emmanuela Spiteri
PR@mavenir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom